Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Squamous Cell Carcinoma of Head and Neck 3Oropharyngeal Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Sarcoma, Ewing 1Renal Pelvis and Ureter Urothelial Carcinoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Peritoneal Neoplasms 1Nasopharyngeal Carcinoma 1Muscle Invasive Bladder Urothelial Carcinoma 1Mouth Neoplasms 1Melanoma 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Lymphoid Interstitial Pneumonia 1Leukemia, Myeloid, Acute 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Extensive Stage Lung Small Cell Carcinoma 1Carcinoma, Squamous Cell 1Carcinoma 1Adenocarcinoma of Lung 1Adenocarcinoma Of Esophagus 1

Interventions

atezolizumab 1Specimen Handling 1Radiotherapy 1Radiation 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Extensive Stage Lung Small Cell Carcinoma × Specimen Handling × Clear all
NCT04402788 2026-06-02

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

National Cancer Institute (NCI)

Phase 2/3 Recruiting
138 enrolled

Extensive Stage Lung Small Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡